{"prompt": "['2017N331008_0', 'CONFIDENTIAL', '208090', 'IP accountability will be evaluated using pill counts of unused DTG/3TC FDC only', 'and not CAR. This assessment will be conducted each time the participant receives a', 'new (refill) supply of DTG/3TC FDC through the Withdrawal visit or study', 'completion. IP accountability records must be maintained throughout the course of', \"the study. These data will be recorded in the participant's eCRF but will not be\", 'summarised for analysis purposes.', 'Please refer to Appendix 14 in Section 11.14 for study management information', 'during the COVID-19 pandemic.', '6.6.', 'Treatment Compliance', 'When participants self-administer study interventions at home, compliance with', 'DTG/3TC FDC or CAR will be assessed through querying the participant during the site', 'visits and documented in the source documents and eCRF. A record of the number of', 'DTG/3TC FDC tablets dispensed to and taken by each participant must be maintained', 'and reconciled with study intervention and compliance records. Intervention start and', 'stop dates, including dates for treatment delays will also be recorded in the case report', 'form (eCRF) for both DTG/3TC FDC and CAR.', '6.7.', 'Concomitant Therapy', 'Refer to Appendix 6 for a full list of prohibited medications. The Medical Monitor should', 'be contacted if there are any questions regarding concomitant or prior therapy.', 'Participants should be advised to notify their investigator of any current or proposed', 'concomitant medication, whether prescribed or over-the-counter, because of the potential', 'DDIs between such treatments and the study interventions. The investigator should', 'evaluate any potential DDIs at every visit, including reviewing the most current version', 'of the U.S. or local prescribing information for DTG, 3TC and CAR, especially if any', 'new concomitant medications are reported by participants. All concomitant medications', '(including oral contraception, implants or oral or topical hormone replacement therapy)', 'taken during the study will be recorded in the eCRF. The minimum requirement is that', 'the drug name, route, and the dates of administration are to be recorded.', 'Concomitant medications (prescription and non-prescription) should be prescribed by the', 'relevant health care provider/investigator and administered only as medically necessary', 'during the Randomized and Continuation phases of the study (except prohibited', 'medications described in Section 11.6). Chemoprophylaxis for HIV-associated', 'conditions is encouraged, if appropriate, at the discretion of the participant and their', 'physician. All concomitant medications, blood products, and vaccines taken during the', 'study will be recorded in the eCRF with dates of administration.', '6.7.1.', 'Permitted Medications and Non-Drug Therapies', 'Because non-HIV vaccines may cause a temporary increase in the level of HIV-1 plasma', 'RNA, it is highly recommended that a vaccine, if necessary, be given during or', 'immediately after a scheduled visit after all laboratory tests have been drawn and only', '47']['2017N331008_06', 'CONFIDENTIAL', '208090', 'when scheduled visits are >4 weeks apart. This approach will minimize the risk of non-', 'specific increases in the level of HIV-1 plasma RNA at the next scheduled assessment.', 'DTG/3TC FDC should be administered 2 hours before or 6 hours after taking antacid or', 'laxative products containing polyvalent cations (e.g. aluminium and magnesium),', 'sucralfate, or calcium supplements. Proton pump inhibitors and H2-antagonists may be', 'used in place of antacids with no scheduling restrictions. Concurrent administration with', 'multivitamins is acceptable. Iron supplements can be taken with IP provided that all are', 'taken together with a meal. Under fasted conditions, DTG +3TC should be given 2 hours', 'prior to OR 6 hours after iron supplements.', 'Metformin concentrations may be increased by DTG. A dose adjustment of metformin', 'should be considered when starting and stopping co-administration of dolutegravir with', 'metformin, to maintain glycaemic control.', 'Clinical monitoring is recommended for participants taking methadone, as methadone', 'maintenance therapy may need to be adjusted in some participants.', 'Non-protocol defined treatments or medical interventions (e.g., physical therapy,', 'radiotherapy, surgical procedures) are permitted during the study for appropriate medical', 'management of the participant.', '6.8.', 'Treatment after the End of the Study', 'The investigator is responsible for ensuring that consideration has been given to the post-', \"study care of the participant's medical condition, whether or not ViiV is providing\", 'specific post-study treatment.', 'All participants on DTG/3TC FDC who successfully complete 52 weeks of treatment will', 'have the opportunity to receive DTG/3TC FDC once daily in a Continuation Phase until:', 'DTG and 3TC are each locally approved for use as part of a 2-drug regimen, and', 'each of the single entities of DTG and 3TC are available to participants (e.g.,', 'through public health services or through their usual health insurance payer), or', 'the actual DTG/3TC FDC tablet, if required by local regulations, is available, or', 'the participant no longer derives clinical benefit, or', 'the participant meets a protocol-defined reason for discontinuation, or', 'development of the DTG plus 3TC 2-drug regimen is terminated.', 'The Continuation Phase is not applicable for participants in Sweden and Denmark.', 'The purpose of the Continuation Phase is to ensure provision of DTG/3TC FDC.', 'Assessments during the Continuation Phase are limited and will include some safety', 'laboratory assessments.', '48']\n\n###\n\n", "completion": "END"}